The mitogen-activated protein kinase kinase 4 has a pro-oncogenic role in skin cancer

Cancer Research

Volumn 70, Issue 14, 2010, Pages 5797-5806

  Finegan, Katherine G ^a   Tournier, Cathy ^a  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; MITOGEN ACTIVATED PROTEIN KINASE KINASE 4; PROTEIN C JUN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; EPIDERMIS; GENE ACTIVATION; GENE DELETION; GENE MUTATION; MOUSE; NONHUMAN; ONCOGENE RAS; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; SKIN CARCINOGENESIS; SKIN PAPILLOMA;

9,10-DIMETHYL-1,2-BENZANTHRACENE; ANIMALS; CARCINOGENS; CELL TRANSFORMATION, NEOPLASTIC; ENZYME ACTIVATION; FEMALE; GENES, RAS; INBREEDING; MALE; MAP KINASE KINASE 4; MICE; SKIN; SKIN NEOPLASMS;

EID: 77955045781     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-09-3669     Document Type: Article

References (40)

1. Wang X, Destrument A, Tournier C. Physiological roles of MKK4 and MKK7: insights from animal models. Biochim Biophys Acta 2006; 1773:1349-57.
2. Wang X, Nadarajah B, Robinson AC, et al. Mitogen-activated protein kinase kinase 4 is an essential activator of the c-Jun N-terminal protein kinase during brain development. Mol Cell Biol 2007;27:7935-46.
3. Branco D, Tanaka N, Jaeschke A, et al. Mechanism of p38 MAP kinase activation in vivo. Genes Dev 2003;17:1969-78.
4. Yang S, Sharrocks AD, Whitmarsh AJ. Transcriptional regulation by the MAP kinase signaling cascades. Gene 2003;320:3-21.
5. Vogt PK. Jun, the oncoprotein. Oncogene 2001;20:2365-77.
6. Behrens A, Jochum W, Sibilia M, Wagner EF. Oncogenic transformation by ras and fos is mediated by c-Jun N-terminal phosphorylation. Oncogene 2000;19:2657-63.
7. Kennedy NJ, Sluss HK, Jones SN, Bar-Sagi D, Flavell RA, Davis RJ. Suppression of Ras-stimulated transformation by the JNK signal transduction pathway. Genes Dev 2003;17:629-37.
8. Chen N, Nomura M, She QB, et al. Suppression of skin tumorigenesis in c-Jun NH(2)-terminal kinase-2-deficient mice. Cancer Res 2001;61:3908-12.
9. She QB, Chen N, Bode AM, Flavell RA, Dong Z. Deficiency of c-Jun-NH(2)-terminal kinase-1 in mice enhances skin tumor development by 12-O-tetradecanoylphorbol-13-acetate. Cancer Res 2002;62: 1343-8.
10. Hess P, Pihan G, Sawyers CL, Flavell RA, Davis RJ. Survival signaling mediated by c-Jun NH(2)-terminal kinase in transformed B lymphoblasts. Nat Genet 2002;32:201-5.
11. Su GH, Hilgers W, Shekher MC, et al. Alterations in pancreatic, biliary, and breast carcinomas support MKK4 as a genetically targeted tumor suppressor gene. Cancer Res 1998;58:2339-42.
12. Wang L, Pan Y, Dai JL. Evidence of MKK4 pro-oncogenic activity in breast and pancreatic tumors. Oncogene 2004;23:5978-85.
13. Cunningham SC, Gallmeier E, Hucl T, et al. Targeted deletion of MKK4 in cancer cells: a detrimental phenotype manifests as decreased experimental metastasis and suggests a counterweight to the evolution of tumor-suppressor loss. Cancer Res 2006;66:5560-4.
14. Whitmarsh AJ, Davis RJ. Role of mitogen-activated protein kinase kinase 4 in cancer. Oncogene 2007;26:3172-84.l.
15. Frame S, Balmain A. Integration of positive and negative growth signals during ras pathway activation in vivo. Curr Opin Genet Dev 2000;10:106-13.
16. Sharma SV, Gajowniczek P, Way IP, et al. A common signaling cascade may underlie "addiction" to the Src, BCR-ABL, and EGF receptor oncogenes. Cancer Cell 2006;10:425-35.
17. Indra AK, Li M, Brocard J, et al. Targeted somatic mutagenesis in mouse epidermis. Horm Res 2000;54:296-300.
18. Kaufman MH. Morphological stages of postimplantation embryonic development. In: Copp AJ, Cockroft DL, editors. Postimplantation mammalian embryos: A Practical Approach. Oxford: IRL Press; 1990, p. 81-91.
19. Kayahara M, Wang X, Tournier C. Selective regulation of c-jun gene expression by the mitogen-activated protein kinases via the TPA-responsive element and the myocyte enhancer factor 2 binding sites. Mol Cell Biol 2005;25:3784-92.
20. Sauer B. Inducible gene targeting in mice using the Cre/lox system. Methods 1998;14:381-92.
21. Chakravarti D, Pelling JC, Cavalieri EL, Rogan EG. Relating aromatic hydrocarbon-induced DNA adducts and c-H-ras mutations in mouse skin papillomas: the role of apurinic sites. Proc Natl Acad Sci U S A 1995;92:10422-6.
22. Angel P, Hattori K, Smeal T, Karin M. The jun proto-oncogene is positively autoregulated by its product, Jun/AP-1. Cell 1988;55: 875-85.
23. Zenz R, Scheuch H, Martin P, et al. c-Jun regulates eyelid closure and skin tumor development through EGFR signaling. Dev Cell 2003; 4:879-89.
24. Schreiber M, Kolbus A, Piu F, et al. Control of cell cycle progression by c-Jun is p53 dependent. Genes Dev 1999;13:607-19.
25. Fuchs SY, Adler V, Thomas B, et al. JNK targets p53 ubiquitination and degradation in nonstressed cells. Genes Dev 1998;12:2658-63.
26. Teng DH, Perry WL III, Hogan JK, et al. Human mitogen-activated protein kinase 4 as a candidate tumor suppressor. Cancer Res 1997;57:4177-82.
27. Yoshida BA, Dubauskas Z, Chekmareva MA, Christiano TR, Stadler WM, Rinker-Schaeffer CW. Mitogen-activated protein kinase kinase 4/stress-activated protein/ERK kinase 1 (MKK4/SEK1), a prostate cancer metastasis suppressor gene encoded by human chromosome 17. Cancer Res 1999;59:5483-7.
28. Kim HL, Vander Griend DJ, Yang X, et al. Mitogen-activated protein kinase kinase 4 metastasis suppressor gene expression is inversely related to histological pattern in advancing human prostatic cancers. Cancer Res 2001;61:2833-7.
29. Yamada SD, Hickson JA, Hrobowski Y, et al. Mitogen-activated protein kinase kinase 4 (MKK4) acts as a metastasis suppressor gene in human ovarian carcinoma. Cancer Res 2002;62:6717-23.
30. Xin W, Yun KJ, Ricci F, et al. MAP2K4/MKK4 expression in pancreatic cancer: genetic validation of immunohistochemistry and relationship to disease course. Clin Cancer Res 2004;10:8516-20.
31. Wu CW, Li AF, Chi CW, et al. Human gastric cancer kinase profile and prognostic significance of MKK4 kinase. Am J Pathol 2000; 156:2007-15.
32. Huang C, Huang K, Wang C, et al. Overexpression of mitogen-activated protein kinase kinase 4 and nuclear factor-κB in laryngeal squamous cell carcinoma: a potential indicator for poor prognosis. Oncol Rep 2009;22:89-95.
33. Tournier C, Hess P, Yang DD, et al. Requirement of JNK for stress-induced activation of the cytochrome c-mediated death pathway. Science 2000;288:870-4.
34. Kennedy NJ, Davis RJ. Role of JNK in tumor development. Cell Cycle 2003;2:199-201.
35. Sancho R, Nateri AS, de Vinuesa AG, et al. JNK signalling modulates intestinal homeostasis and tumourigenesis in mice. EMBO J 2009; 28:1843-54.
36. Chen N, She QB, Bode AM, Dong Z. Differential gene expression profiles of Jnk1- and Jnk2-deficient murine fibroblast cells. Cancer Res 2002;62:1300-4.
37. Sabapathy K, Hochedlinger K, Nam SY, Bauer A, Karin M, Wagner EF. Distinct roles for JNK1 and JNK2 in regulating JNK activity and c-Jun-dependent cell proliferation. Mol Cell 2004;15:713-25.
38. Jaeschke A, Karasarides M, Ventura JJ, et al. JNK2 is a positive regulator of the cJun transcription factor. Mol Cell 2006;23:899-911.
39. Zenz R, Wagner EF. Jun signalling in the epidermis: from developmental defects to psoriasis and skin tumors. Int J Biochem Cell Biol 2006;38:1043-9.
40. Kemp CJ, Donehower LA, Bradley A, Balmain A. Reduction of p53 gene dosage does not increase initiation or promotion but enhances malignant progression of chemically induced skin tumors. Cell 1993; 74:813-22.